Abstract

The multi-subunit translation initiation factor eIF2B is a control node for protein synthesis. eIF2B activity is canonically modulated through stress-responsive phosphorylation of its substrate eIF2. The eIF2B regulatory subcomplex is evolutionarily related to sugar-metabolizing enzymes, but the biological relevance of this relationship was unknown. To identify natural ligands that might regulate eIF2B, we conduct unbiased binding- and activity-based screens followed by structural studies. We find that sugar phosphates occupy the ancestral catalytic site in the eIF2Bα subunit, promote eIF2B holoenzyme formation and enhance enzymatic activity towards eIF2. A mutant in the eIF2Bα ligand pocket that causes Vanishing White Matter disease fails to engage and is not stimulated by sugar phosphates. These data underscore the importance of allosteric metabolite modulation for proper eIF2B function. We propose that eIF2B evolved to couple nutrient status via sugar phosphate sensing with the rate of protein synthesis, one of the most energetically costly cellular processes.

The activity of translation initiation factor eIF2B is known to be modulated through stress-responsive phosphorylation of its substrate eIF2. Here, the authors uncover the regulation of eIF2B by the binding of sugar phosphates, suggesting a link between nutrient status and the rate of protein synthesis.

Details

Title
Sugar phosphate activation of the stress sensor eIF2B
Author
Qi, Hao 1 ; Jin-Mi, Heo 2 ; Nocek, Boguslaw P 3 ; Hicks, Kevin G 4   VIAFID ORCID Logo  ; Stoll, Vincent S 3 ; Remarcik Clint 5 ; Hackett, Sean 5   VIAFID ORCID Logo  ; LeBon, Lauren 5   VIAFID ORCID Logo  ; Jain Rinku 3 ; Eaton, Dan 5 ; Rutter, Jared 6   VIAFID ORCID Logo  ; Wong Yao Liang 7   VIAFID ORCID Logo  ; Sidrauski Carmela 7   VIAFID ORCID Logo 

 Calico Life Sciences LLC, South San Francisco, USA 
 Calico Life Sciences LLC, South San Francisco, USA; Loxo Oncology at Lilly, South San Francisco, USA 
 Research & Development, AbbVie, North Chicago, USA (GRID:grid.431072.3) (ISNI:0000 0004 0572 4227) 
 University of Utah School of Medicine, Department of Biochemistry, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096) 
 Calico Life Sciences LLC, South San Francisco, USA (GRID:grid.431072.3) 
 University of Utah School of Medicine, Department of Biochemistry, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096); University of Utah School of Medicine, Howard Hughes Medical Institute, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096) 
 Calico Life Sciences LLC, South San Francisco, USA (GRID:grid.223827.e) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2538878020
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.